Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT
- 1 October 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 42 (S2), S40-S46
- https://doi.org/10.1038/bmt.2008.282
Abstract
Allogeneic haematopoietic SCT (HSCT) induces CRs in most patients with CML. With the excellent short-term treatment results induced by imatinib (IMA), attitudes have changed and only a minority of children are now transplanted upfront. This review addresses the role of IMA in children with CML, focusing on the starting dose of IMA, possible adverse effects, timing of HSCT in children, duration of IMA treatment and monitoring of treatment efficacy to unravel failure of early treatment of IMA as well as treatment of CML relapse after HSCT. As the paediatric experience with IMA is still very limited, many answers and algorithms are adapted from CML in adults. Basically, HSCT should be postponed to achieve an optimal tumour cell reduction by IMA treatment. Children with a low-risk EBMT score should undergo HSCT within 2 years after diagnosis to avoid prolonged exposure and unknown late effects of IMA. Without a perfectly HLA-matched donor, HSCT may be postponed until CML becomes refractory to IMA. As realized in the presently activated international trial CML-paed II, this approach represents a risk-adapted therapy with the benefit of being tailored to the needs and profile of an individual patient.Keywords
This publication has 46 references indexed in Scilit:
- Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacyLeukemia, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaBlood, 2006
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantationLeukemia, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Inhibition of c-fms by Imatinib: Expanding the Spectrum of TreatmentCell Cycle, 2005
- Chronic Myelogenous LeukemiaHematology-American Society Hematology Education Program, 2001
- Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1997
- Die Behandlung der chronisch myeloischen Leukämie (CML) bei Kindern und Jugendlichen - Konzept der multizentrischen Pilotstudie CML-pädKlinische Padiatrie, 1996